NRAS and melanoma: Analyzing the same database, we observed that the NRAS Q61R mutation was the most prevalent in melanoma patients (12.4%) (Supplementary Figure S1A), but unlike the BRAFV600E mutation, it did not alter the TMB (Supplementary Figure S1B).